Rigel Pharmaceuticals Inc Stock Price, News & Analysis

Rigel Pharmaceuticals (NASDAQ:RIGL), a biotechnology company focused on hematologic disorders and cancer, has announced its participation in four major investor conferences this September 2025.

The company's leadership, including CEO Raul Rodriguez and CFO Dean Schorno, will attend the Citi's Biopharma Back to School Conference, Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, and H.C. Wainwright Global Investment Conference. Company presentations are scheduled at Cantor (September 3, 8:35 a.m. ET) and H.C. Wainwright (September 9, 1:30 p.m. ET), with webcasts available through Rigel's investor relations website.

Rigel Pharmaceuticals (Nasdaq: RIGL) reported strong Q2 2025 financial results, with total revenue of $101.7 million, including net product sales of $58.9 million (76% YoY growth) and contract revenues of $42.7 million. The company generated $59.6 million in net income and increased its cash position to $108.4 million.

Key highlights include TAVALISSE sales of $40.1 million (52% YoY growth), GAVRETO sales of $11.8 million, and REZLIDHIA sales of $7.0 million (36% YoY growth). Rigel raised its 2025 guidance, projecting total revenue of $270-280 million, including net product sales of $210-220 million.

The company completed enrollment in Phase 1b study of R289 for R/R lower-risk MDS and expects to share updated data and initiate dose expansion later this year.

Rigel Pharmaceuticals (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer therapies, will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025.

The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss financial results and provide a business update. Investors can join via phone or access the webcast through Rigel's investor relations website, where it will remain available for replay for 90 days.

Rigel Pharmaceuticals (NASDAQ: RIGL) has announced the granting of inducement awards to new employees under NASDAQ Listing Rule 5635(c)(4). The company granted a total of 23,075 stock options and restricted stock units to 10 non-executive employees. These equity awards will vest over a four-year period with a one-year cliff.

Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer.

Rigel Pharmaceuticals (Nasdaq: RIGL), a commercial stage biotechnology company specializing in hematologic disorders and cancer treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Raul Rodriguez will deliver a company overview on June 4, 2025, at 12:50 p.m. ET in New York. The presentation will be accessible via live webcast through Rigel's Investor Relations website.

Founded in 1996 and headquartered in South San Francisco, Rigel focuses on developing novel therapies for patients with blood disorders and cancer. Interested parties can access the presentation through www.rigel.com.

Rigel Pharmaceuticals (NASDAQ: RIGL) announced seven upcoming poster presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress, showcasing data for GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib). Key highlights include:

For GAVRETO in RET fusion-positive NSCLC:

• Overall response rate: 70.3%
• Median duration of response: 19.1 months
• Median overall survival: 44.3 months
• Median progression-free survival: 13.1 months

For REZLIDHIA in mIDH1 R/R AML:

• Higher response rates in patients with 1-2 prior regimens vs ≥3 prior therapies
• 50% overall response rate in primary refractory patients
• Demonstrated efficacy across IDH1-R132 mutation types

The presentations will take place at ASCO (May 30-June 3, 2025) in Chicago and EHA (June 12-15, 2025) in Milan.

Rigel Pharmaceuticals (RIGL) reported strong Q1 2025 financial results with total revenue of $53.3 million, including $43.6 million in net product sales (68% YoY growth) and $9.8 million in contract revenues. The company generated $11.4 million in net income, compared to a loss in Q1 2024. Product sales were driven by TAVALISSE ($28.5M), GAVRETO ($9.0M), and REZLIDHIA ($6.1M). R289 received Orphan Drug and Fast Track designations for MDS treatment. The company maintains its 2025 outlook of $200-210 million in total revenue and expects positive net income for the full year. Additionally, Rigel anticipates recognizing $40 million in non-cash revenue in Q2 2025 related to its Lilly collaboration.

Rigel Pharmaceuticals (Nasdaq: RIGL) has scheduled its first quarter 2025 financial results announcement and business update for Tuesday, May 6, 2025, after market close. The company will host a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Investors can join the call through two options:

• Phone: 877-407-3088 (domestic) or 201-389-0927 (international)
• Webcast: Available through the Investor Relations section at www.rigel.com

Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer. The webcast will be archived and accessible for replay through the company website for 90 days following the call.

Rigel Pharmaceuticals (Nasdaq: RIGL) has announced the granting of inducement awards under its Inducement Plan, as approved by the company's Compensation Committee. The grants, made in accordance with NASDAQ Listing Rule 5635(c)(4), consist of 23,350 stock options and restricted stock units awarded to seven non-executive employees.

These equity awards will vest over a four-year period with a one-year cliff vesting schedule. The grants serve as inducement material for employees entering into employment with Rigel, a biotechnology company founded in 1996 that focuses on developing therapies for hematologic disorders and cancer.